Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
Background.Carfilzomib, lenalidomide, and dexamethasone (KRd) have been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) based on ASPIRE clinical trial.Aim.Analysis of efficacy and safety of KRd in routine clinical practice.Materials and methods.The prospective analysis included patients with MM who received at least on